ISHL12 Program at a Glance

Saturday (22.10.2022)

Sunday (23.10.2022)

Monday (24.10.2022)

Großer Saal

07:30–09:00
Interactive Case Discussion

T. Illidge
J. Zijlstra

Case presentation: Greyzone Lymphoma
Case presentation: Anti-PD1 Failure
- G. Collins
Case presentation: COVID19 immunity in lymphoma
- S. Mellinghoff
Case presentation: Primary progressive HL
- A. Jacob

Großer Saal

07:30–09:00
Advanced Stages

O. Casasnovas
J. Radford

Why I recommend BV-AVD
- R. Advani
Why I recommend PET-guided ABVD
- P. Johnson
Why I recommend PET-adapted escalated BEACOPP
- P. Borchmann
Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective
- M. Dreyling
- J. Richardson
- S. Wells
WS Report: Learning through International Collaboration
- P. Borchmann
- C. Moskowitz

+ 2 Oral Abstract presentations

07:30

08:45–10:15
Seminars and Workshops (parallel sessions)

Seminar: Living beyond Lymphoma
- L. Specht
- F. van Leeuwen
Workshop: The HL Microenvironment
- A. Rosenwald
- M. Shipp
Joint EHA-ISHL Symposium
- P. Borchmann
- M. Dreyling
Workshop: PET beyond Deauville
- S. Barrington
- M. Hutchings
- C. Kobe
Workshop: Innovation for Older Patients
- P. Bröckelmann
- A. Fosså

09:00

Coffee Break

Großer Saal

09:15–10:15
Emerging Cellular Therapies – a Role in HL?

S. Ansell
P. Borchmann

Emerging indications for cellular therapy
- P. Borchmann
tba
Cellular Therapy in HL
- B. Savoldo

Großer Saal

09:15–10:15
Special Situations in HL

R. Hoppe
M. Kersten

HL in Pregnancy
- D. Dierickx
HIV-positive HL
- O. Baiocchi
alloSCT in the era of anti-PD1
- A. Sureda

09:15

10:15

Coffee Break

10:30–12:00
Seminars and Workshops (parallel sessions)

Seminar: Radiotherapy: Identifying the Beneficiaries
- C. Baues
- J. Yahalom
Seminar: Learning from Pediatric HL
- J. Friedberg
- C. Mauz-Körholz
Workshop: Bringing Liquid Biopsy to Patients
- S. Borchmann
- D. Rossi
Workshop: NLPHL
- M. Binkley
- D. Eichenauer
- S. Hartmann
Workshop: Learning through International Collaboration
- P. Borchmann
- A. Moskowitz

Großer Saal

10:30–12:00
Living beyond Lymphoma

M. Björkholm
F. van Leeuwen

TBA
GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study
- K. Behringer
WS Report: Living beyond Lymphoma
- L. Specht
- F. van Leeuwen

+ 3 Oral Abstract presentations

Großer Saal

10:30–12:00
Genomics, Biology and Microenvironment

W. Klapper
R. Küppers

Biological Classification of HL by Liquid Biopsy
- S. Borchmann
Single Cell Transcriptomics of HL
- C. Steidl
WS Report: Learning through International Collaboration
- P. Borchmann
- C. Moskowitz

+ 3 Oral Abstract presentations

10:30

12:00

Coffee Break

Großer Saal

12:15–13:45
Opening paths to the next chapters of lymphoma treatmen

by Beigene

Welcome and Introduction to the topic
- P. Borchmann
Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma
- P. Bröckelmann
The challenge of the older patient in lymphoma therapy
- G. Collins
New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies
- P. Zinzani
Summary and farewell
- S. Borchmann

Großer Saal

12:15–13:45
Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

by MSD

P. Borchmann

Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?
- P. Borchmann
The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma
- B. von Tresckow
Strategies to enhance checkpoint inhibition
- P. Bröckelmann

Großer Saal

12:15–13:45
Bridging the gap between efficacy and toxicity in the treatment of stage IV Hodgkin lymphoma

by Takeda

G. Collins
A. Herrera
P. Zinzani

Hot Off the Press: The Latest Data for ECHELON-1
Case Study #1 Female, early-30s
Case Study #2 Male, late-70s
Case Study #3 Male, mid-50s
Q&A

12:15

13:45

Coffee Break

Großer Saal

14:00–15:30
Early Stages

M. André
H. Eich

Standard treatment of early-stage HL (Note: with RAPID Update)
- J. Radford
Individual risk assessment of RT in HL
- R. Hoppe
WS Report: NLPHL
- M. Binkley
- D. Eichenauer
- S. Hartmann

+ 3 Oral Abstract presentations

Großer Saal

14:00–15:30
Older and Frail Patients

R. Cordoba
A. Evens

Managing an Older Lymphoma Patient
- R. Cordoba
Treatment Strategies in Older HL Patients
- A. Evens
Workshop Report: Innovation for Older patients
- P. Bröckelmann
- A. Fosså

+ 3 Oral Abstract presentations

Großer Saal

14:00–15:30
Relapsed / Refractory HL

R. Advani
C. Moskowitz

1ˢᵗ Relapse of HL
- C. Moskowitz
Novel developments in R/R HL
- G. Collins
WS Report: PET beyond Deauville
- S. Barrington
- M. Hutchings
- C. Kobe

+ 3 Oral Abstract presentations

14:00

15:30

Coffee Break

Großer Saal

15:30–16:00
Closing Remarks

Conference Highlights
- R. Advani

Großer Saal

16:00–17:30
CAR T cell therapy in B Cell NHL: Status quo and future perspectives

by Bristol-Myers Squibb

C. Scheid

Status quo of CAR T cell therapy for r/r DLBCL
- P. Borchmann
New perspective for the treatment of r/r CLL
CAR T – Lessons Learned
- C. Scheid

Großer Saal

16:00–17:30
Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

by Takeda

Welcome and introduction
- A. Sureda
Navigating Complex Treatment Decisions in R/R HL
- T. Vassilakopoulos
Challenging Case Study #1
- M. Hutchings
Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL
- A. Sureda
Challenging Case Study #2
- M. Hutchings

Großer Saal

16:00–17:30
Farewell

16:00

17:30

Coffee Break

Großer Saal

18:00–19:00
Opening and Award Ceremony

Welcoming Address
- A. Engert
Award Ceremony
- P. Borchmann
- S. Borchmann
- P. Bröckelmann
- D. Eichenauer
Introduction to the Keynote Lecturer
- V. Diehl
Keynote Lecture
- U. Sahin

Großer Saal

18:00–19:30
Immunotherapy

P. Armand
P. Zinzani

New findings and new challenges since last ISHL
- S. Ansell
Vision Corner: The future of translational science in Hodgkin
- M. Shipp
Vision Corner: Best use of PD1 blockade in front-line
- P. Bröckelmann
Vision Corner: Leveraging PD1 blockade for cure
- G. Collins

+ 2 Oral Abstract presentations

18:00

19:00

Foyer (Ground Floor)

19:00–20:30
Poster Session

Foyer (First Floor)

19:00
Welcome Reception

20:30

07:30–09:00 Interactive Case Discussion

Case presentation: Greyzone Lymphoma

Case presentation: Anti-PD1 Failure

Case presentation: COVID19 immunity in lymphoma

Case presentation: Primary progressive HL

07:30–09:00 Advanced Stages

Why I recommend BV-AVD

Why I recommend PET-guided ABVD

Why I recommend PET-adapted escalated BEACOPP

Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective

WS Report: Learning through International Collaboration

08:45–10:15 Seminars and Workshops (parallel sessions)

Seminar: Living beyond Lymphoma

Workshop: The HL Microenvironment

Joint EHA-ISHL Symposium

Workshop: PET beyond Deauville

Workshop: Innovation for Older Patients

09:15–10:15 Emerging Cellular Therapies – a Role in HL?

Emerging indications for cellular therapy

tba

Cellular Therapy in HL

09:15–10:15 Special Situations in HL

HL in Pregnancy

HIV-positive HL

alloSCT in the era of anti-PD1

10:30–12:00 Seminars and Workshops (parallel sessions)

Seminar: Radiotherapy: Identifying the Beneficiaries

Seminar: Learning from Pediatric HL

Workshop: Bringing Liquid Biopsy to Patients

Workshop: NLPHL

Workshop: Learning through International Collaboration

10:30–12:00 Living beyond Lymphoma

TBA

GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study

WS Report: Living beyond Lymphoma

10:30–12:00 Genomics, Biology and Microenvironment

Biological Classification of HL by Liquid Biopsy

Single Cell Transcriptomics of HL

WS Report: Learning through International Collaboration

12:15–13:45 Opening paths to the next chapters of lymphoma treatmen

Welcome and Introduction to the topic

Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma

The challenge of the older patient in lymphoma therapy

New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies

Summary and farewell

12:15–13:45 Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?

The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma

Strategies to enhance checkpoint inhibition

12:15–13:45 Bridging the gap between efficacy and toxicity in the treatment of stage IV Hodgkin lymphoma

Hot Off the Press: The Latest Data for ECHELON-1

Case Study #1 Female, early-30s

Case Study #2 Male, late-70s

Case Study #3 Male, mid-50s

Q&A

14:00–15:30 Early Stages

Standard treatment of early-stage HL (Note: with RAPID Update)

Individual risk assessment of RT in HL

WS Report: NLPHL

14:00–15:30 Older and Frail Patients

Managing an Older Lymphoma Patient

Treatment Strategies in Older HL Patients

Workshop Report: Innovation for Older patients

14:00–15:30 Relapsed / Refractory HL

1ˢᵗ Relapse of HL

Novel developments in R/R HL

WS Report: PET beyond Deauville

15:30–16:00 Closing Remarks

Conference Highlights

16:00–17:30 CAR T cell therapy in B Cell NHL: Status quo and future perspectives

Status quo of CAR T cell therapy for r/r DLBCL

New perspective for the treatment of r/r CLL

CAR T – Lessons Learned

16:00–17:30 Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

Welcome and introduction

Navigating Complex Treatment Decisions in R/R HL

Challenging Case Study #1

Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL

Challenging Case Study #2

16:00–17:30 Farewell

07:30–09:00
Interactive Case Discussion

07:30–09:00
Advanced Stages

08:45–10:15
Seminars and Workshops (parallel sessions)

09:15–10:15
Emerging Cellular Therapies – a Role in HL?

09:15–10:15
Special Situations in HL

10:30–12:00
Seminars and Workshops (parallel sessions)

10:30–12:00
Living beyond Lymphoma

10:30–12:00
Genomics, Biology and Microenvironment

12:15–13:45
Opening paths to the next chapters of lymphoma treatmen

12:15–13:45
Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

12:15–13:45
Bridging the gap between efficacy and toxicity in the treatment of stage IV Hodgkin lymphoma

14:00–15:30
Early Stages

14:00–15:30
Older and Frail Patients

14:00–15:30
Relapsed / Refractory HL

15:30–16:00
Closing Remarks

16:00–17:30
CAR T cell therapy in B Cell NHL: Status quo and future perspectives

16:00–17:30
Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

16:00–17:30
Farewell

18:00–19:00
Opening and Award Ceremony

18:00–19:30
Immunotherapy

19:00–20:30
Poster Session

19:00
Welcome Reception